Cardiovascular Phase 3 Deal Benchmarks — Europe (2026)

Understanding Cardiovascular Deal Benchmarks at Phase 3

Phase 3 Cardiovascular licensing deals in Europe territory command a median upfront payment of $345M, with values ranging from $223M at the low end to $449M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the cardiovascular therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $832M to $1.4B, with a median of $1.1B. Royalty rates for cardiovascular assets at this stage typically fall between 8.7% and 16% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.